HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Monoclonal Gammopathy of Undetermined Significance

Conditions characterized by the presence of M protein (Monoclonal protein) in serum or urine without clinical manifestations of plasma cell dyscrasia.
Also Known As:
Monoclonal Gammapathies, Benign; Benign Monoclonal Gammapathies; Benign Monoclonal Gammapathy; Benign Monoclonal Gammopathy; Monoclonal Gammapathy, Benign; Monoclonal Gammopathy, Benign; Benign Monoclonal Gammopathies; Monoclonal Gammapathy of Undetermined Significance; Monoclonal Gammopathies, Benign
Networked: 932 relevant articles (29 outcomes, 75 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1. Multiple Myeloma
2. Paraproteinemias (Monoclonal Gammopathy)
3. Waldenstrom Macroglobulinemia (Macroglobulinemia)
4. Monoclonal Gammopathy of Undetermined Significance
5. Neoplasms (Cancer)

Experts

1. Kyle, Robert A: 28 articles (01/2022 - 09/2002)
2. Rajkumar, S Vincent: 28 articles (01/2022 - 09/2002)
3. Landgren, Ola: 23 articles (12/2021 - 12/2006)
4. Dispenzieri, Angela: 18 articles (01/2022 - 07/2004)
5. Terpos, Evangelos: 11 articles (11/2022 - 09/2004)
6. Larson, Dirk R: 10 articles (12/2019 - 11/2003)
7. Vacca, Angelo: 9 articles (01/2022 - 09/2009)
8. Bladé, Joan: 9 articles (10/2021 - 05/2002)
9. Varettoni, Marzia: 9 articles (04/2021 - 03/2013)
10. Rosiñol, Laura: 8 articles (10/2021 - 05/2002)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Monoclonal Gammopathy of Undetermined Significance:
1. Immunoglobulin G (IgG)IBA
2. Monoclonal AntibodiesIBA
3. Proteins (Proteins, Gene)FDA Link
4. CytokinesIBA
5. ThymidineIBA
6. Bortezomib (Velcade)FDA Link
7. Dexamethasone (Maxidex)FDA LinkGeneric
8. Immunoglobulin M (IgM)IBA
9. Immunoglobulins (Immunoglobulin)IBA
10. Interleukin-6 (Interleukin 6)IBA

Therapies and Procedures

1. Therapeutics
2. Stem Cell Transplantation
3. Drug Therapy (Chemotherapy)
08/01/2016 - "This case highlights the need to consider neoplastic interstitial plasma cell infiltration systematically in patients diagnosed with an apparently benign monoclonal gammopathy and to consider adaptation of the chemotherapy regimen, to improve renal function."
01/01/2018 - "The patient was suspected of having sporadic late-onset nemaline myopathy with monoclonal gammopathy of undetermined significance (SLONM-MGUS), because of resistant to chemotherapy and second opinion suggestion. "
01/01/2015 - "This article includes three points: 1) the progression rate of monoclonal gammopathy of undetermined significance (MGUS) to MM, 2) the effect of radiation to prevalence of MM, and 3) secondary malignancy after chemotherapy used to treat MM. The risk of progression from MGUS to MM is 1% per year. "
01/01/2006 - "In presented study was evaluated serum sCD138 level in 14 patients with monoclonal gammopathy of undetermined significance (MGUS) and in 17 patients with multiple myeloma (MM), all MM patients were treated by high-dose chemotherapy regimen with subsequent autologous transplantation of peripheral blood stem cells. "
01/01/1988 - "The second group (n = 50; 132 +/- 54 plasma cells per square millimeter bone marrow) with plasmacytic differentiation of infiltrates, had to be further divided into one component with evidence for initial or residual MM following chemotherapy (n = 27), another with obviously monoclonal gammopathy of undetermined significance--benign monoclonal gammopathy (BMG, n = 6), and a final set of cases with a reactive plasmacytosis mostly associated with an inflammatory condition (n = 17). "
4. Aftercare (After-Treatment)
5. Enzyme Replacement Therapy